A “systems” study led by Denmark’s Aarhus University is offering new insights into kidney metabolism, including links to viral protection. The comprehensive datasets generated by the mouse study hold promise for improving understanding of cell physiology, disease mechanisms, and targeted drug treatments.
A kidney filters 180 liters of blood daily, retaining nutrients through a process called endocytosis and active transport in the kidney cells. The recent study, led by Markus Rinschen from Aarhus Institute of Advanced Studies and the Department of Biomedicine at Aarhus University, evaluated how endocytosis is regulated by the lipid kinase VPS34, an enzyme involved in vesicular trafficking and endocytic sorting of membrane proteins. The process is crucial for the body to obtain the right nutrients, but also to block out the unhealthy ones, such a virus.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Rinschen and colleagues used multiomics, an approach where multiple data sets are combined during analysis to provide a comprehensive view of cell physiology. This approach is hypothesis-free but can quantify the functions of many transporters and enzymes as well as their interactions. This “systems” view showed that a lack of lipid kinase in proximal tubule cells in mice lowered the abundance of nutrient transporters on the cell surface, which was associated with increased urinary loss of lipids, amino acids, sugars and proteins. In addition, the number of viral entry receptors on the cell surface was reduced. Accordingly, treatment with a lipid kinase inhibitor reduced the entry of the virus SARS-CoV-2 in cultured proximal tubular cells and human kidney organoids.
“Our primary goal in this study was to gather and organize novel knowledge of the fundamental processes of cell physiology. Although this is hypothesis-free, these comprehensive large-scale datasets can be central to understand medical problems. In this case, we ultimately improved targeted drug treatment for instance for kidney related diseases or infections,” says Rinschen, lead author. “Of course, more knowledge needs to be gathered before any conclusions regarding human relevance can be made.”
The results of the study—published recently in the journal Science Signaling—show that blocking of the enzyme lipid kinase could be used to treat diseases in which limiting the retention of nutrients gives clinical benefit, such as kidney cancer or diabetes, or to block a viral infection of the kidney.